Titolo	Data di pubblicazione	Autore(i)
1	Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen	2009	Vignani F; Russo L; Tucci M; Motta M; Vellani G; Tampellini M; Papotti M; Dogliotti L; Berruti A.
2	Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis	2008	DOVIO A; GENERALI D; TAMPELLINI M; BERRUTI A; TEDOLDI S; TORTA M; BONARDI S; TUCCI M; ALLEVI G; AGUGGINI S; BOTTINI A; DOGLIOTTI L; ANGELI A
3	Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.	2008	Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F
4	Unusual paraneoplastic neurological syndrome secondary to a well differentiated pancreatic neuroendocrine tumor: A case report and review of the literature	2015	Brizzi, Maria Pia; Sonetto, Cristina; Tampellini, Marco; Di Maio, Massimo; Volante, Marco; Scagliotti, Giorgio V.
5	Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit	2017	Tampellini, Marco; Di Maio, Massimo; Baratelli, Chiara; Anania, Lorenzo; Brizzi, Maria Pia; Sonetto, Cristina; La Salvia, Anna; Scagliotti, Giorgio Vittorio
6	Il trattamento dell'ascite neoplastica: obiettivi e criteri di valutazione	2009	Marco Tampellini; Luigi Dogliotti
7	Thymidine phosphorylase: The unforeseen driver in colorectal cancer treatment?	2018	Tampellini, Marco*; Bironzo, Paolo; Di Maio, Massimo; Scagliotti, Giorgio V
8	The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results from a Large Retrospective Study.	2012	Tampellini M; Ottone A; Bellini E; Alabiso I; Baratelli C; Bitossi R; Brizzi MP; Ferrero A; Sperti E; Leone F; Miraglia S; Forti L; Bertona E; Ardissone F; Berruti A; Alabiso O; Aglietta M; Scagliotti GV.
9	The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients	2006	TAMPELLINI M; SAINI A; ALABISO I; BITOSSI R; BRIZZI MP; SCULLI CM; BERRUTI A; GORZEGNO G; MAGNINO A; SPERTI E; MIRAGLIA S; FORTI L; ALABISO O; AGLIETTA M; HARRIS A; DOGLIOTTI L
10	The prognostic value of some biological parameters (c-ras, p53, Ki67) in patients undergoing radical cystectomy for bladder carcinoma.	1998	D. FONTANA; BELLINA M.; SCOFFONE C.; CAGNAZZI E.; GUERCIO S.; CAPPIA S.; LEONARDO E.; TAMPELLINI M.
11	The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.	2001	DOGLIOTTI L; TAMPELLINI M; STIVANELLO M; GORZEGNO G; FABIANI L
12	The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load	2007	GENERALI D; BERRUTI A; TAMPELLINI M; DOVIO A; TEDOLDI S; BONARDI S; TUCCI M; ALLEVI G; AGUGGINI S; MILANI M; BOTTINI A; DOGLIOTTI L; ANGELI A
13	TGFalfa, EGFR and p70S6K expression in aggressive colorectal cancer (CRC)	2006	M. Tampellini; M. Longo; S. Cappia; E. Bacillo; M. Brizzi; R. Bitossi; C. M. Sculli; I. Alabiso; L. Dogliotti; M. Papotti
14	Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?	2016	Brizzi, Maria Pia; Pignataro, Daniele; Tampellini, Marco; Scagliotti, Giorgio Vittorio; Di Maio, Massimo
15	A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients	2018	Baratelli, Chiara; Zichi, Clizia; Di Maio, Massimo*; Brizzi, Maria Pia; Sonetto, Cristina; Scagliotti, Giorgio Vittorio; Tampellini, Marco
16	Survival of lung surgery patients with pulmonary metastases from colonic neoplasms	2008	M. Tampellini; I. Alabiso; A. Ottone; S. Miraglia; L. Forti; E. Bertona; C. M. Sculli; E. Bellini; O. Alabiso; L. Dogliotti
17	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis	2017	Cremolini, Chiara; Antoniotti, Carlotta; Pietrantonio, Filippo; Berenato, Rosa; Tampellini, Marco; Baratelli, Chiara; Salvatore, Lisa; Marmorino, Federica; Borelli, Beatrice; Nichetti, Federico; Bironzo, Paolo; Sonetto, Cristina; Bartolomeo, Maria Di; de Braud, Filippo; Loupakis, Fotios; Falcone, Alfredo; Di Maio, Massimo
18	Stage IB malignant thymoma in a Lynch syndrome patient with multiple cancers: response to incidental administration of oxaliplatin and 5-fluorouracil	2006	Tampellini M; Alabiso I; Sculli CM; Barberis M; Giachino D; Berruti A; Dogliotti L
19	Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.	2011	Bellini E; Pia A; Brizzi MP; Tampellini M; Torta M; Terzolo M; Dogliotti L; Berruti A.
20	Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy	2007	TAMPELLINI M; BRIZZI MP; BITOSSI R; ALABISO I; SCULLI CM; CHIUSA L; PAPOTTI M; DOGLIOTTI L